The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.
In Nature this week: Plasmodium genomes and evolution, novel developmental disorder loci, and more.
The Cancer Genome Atlas Research Network team uncovered new mutations and amplifications in their cohort of primary cervical cancers.
The firms will target 18 Latin American countries in three years, with the goal of creating a complete HPV diagnostics system for the region.
The firm is also pursuing ovarian cancer screening and head and neck cancer tests using methylation-specific PCR.
The firm's PCR-based products for HPV-associated cancers look at DNA methylation at specific genes and include several sample preparation kits.
An evaluation of more than 5,000 women attending primary cervical cancer screening showed self-collection and physician-collected samples are comparable.
The UK firm anticipates CE marking shortly and will focus on the European and Chinese markets for its multiplex PCR test for human papillomavirus genotyping.
The company's Confidence assays are designed to detect if a woman has a high-risk HPV subtype and, if so, determine her risk of developing cervical pre-cancer or cancer.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.